A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Trial Profile

A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs TT 701 (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Sponsors OPKO Health; Transition Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to an OPKO Health media release, the company plans to initiate this trial in the 4Q 2017.
    • 03 Jul 2017 New trial record
    • 09 May 2017 According to an OPKO Health media release, the company plans to initiate this trial in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top